![Terns Pharmaceuticals, Inc. logo](/logos/TERN.webp)
Terns Pharmaceuticals, Inc.
NASDAQ:TERN
Overview | Financials
Company Name | Terns Pharmaceuticals, Inc. |
Symbol | TERN |
Currency | USD |
Price | 7.81 |
Market Cap | 549,604,539 |
Dividend Yield | 0% |
52-week-range | 3.26 - 10.03 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Erin Quirk M.D. |
Website | https://www.ternspharma.com |
An error occurred while fetching data.
About Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201,
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD